GM-CSF
GM-CSF is a biological therapy with 116 clinical trials. Currently 16 active trials ongoing. Historical success rate of 78.1%.
Success Metrics
Based on 57 completed trials
Phase Distribution
Phase Distribution
38
Early Stage
61
Mid Stage
12
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
73.1%
57 of 78 finished
26.9%
21 ended early
16
trials recruiting
116
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Therapy for Children With Advanced Stage Neuroblastoma
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Clinical Trials (116)
Therapy for Children With Advanced Stage Neuroblastoma
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 116